Evaluation of Carmeda® Bioactive Surface (CBAS®), Duraflo II and a novel nonspecific protease-modified surface using a new in vitro model simulating cardiopulmonary bypass

Perfusion

Volumn 11, Issue 3, 1996, Pages 229-240

  Yii, M ^a,c   Gourlay, T ^a   Fleming, J ^a   Matata, B ^b   Taylor, K M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; BIOMATERIAL; COMPLEMENT COMPONENT C3A;

BIOCOMPATIBILITY; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; VASCULAR ENDOTHELIUM; ARTICLE; PHYSIOLOGY; SCANNING ELECTRON MICROSCOPY;

BIOCOMPATIBLE MATERIALS; CARDIOPULMONARY BYPASS; COMPLEMENT C3A; HUMANS; MICROSCOPY, ELECTRON, SCANNING; NEUTROPHILS; PLATELET COUNT;

EID: 0029662035     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919601100308     Document Type: Conference Paper

References (35)

1. Courtney JM, Irvine L, Gaylor JDS, Forbes CD, Taylor KM. Blood compatibility in cardiopulmonary bypass. In: Hastings GW ed. Cardiovascular biomaterials. London: Springer-Verlag, 1992: 37-79.
2. Forbes CD, Courtney JM. Thrombosis and artificial surfaces. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD eds. Haemostatis and thrombosis. London: Churchill Livingstone, 1994: 1301-24.
3. Klinkmann H, Falkenhagen D, Courtney JM. Clinical relevance of biocompatibility - the material cannot be divorced from the device. In: Gurland HJ ed. Uremia therapy. Berlin: Springer-Verlag, 1987: 125-38.
4. Courtney JM, Sundaram S, Forbes CD. Extra-corporeal situations: biocompatibility aspects of the application of biomaterials. In: Forbes CD, Cushieri A eds. Management of bleeding disorders in surgical practice. Oxford: Blackwell Scientific, 1993: 236-76.
5. Colton CK, Ward RA, Shaldon S. Scientific basis for assessment of biocompatibility in extracorporeal blood treatment. Nephrol Dial Transplant 1994; 9: 11-17.
6. Ringoir S, Vanholder R. An introduction to biocompatibility. Artif Organs 1986; 10: 20-27.
7. Bonner J, Ritz E. Ethylene oxide (ETO) as a major cause of anaphylactoid reactions in dialysis. Artif Organs 1987; 11: 111-17.
8. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 1993; 70: 253-58.
9. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemostasis 1993; 70: 259-62.
10. Newman S. Neuropsychological and psychological changes following cardiac surgery. In: Smith PL, Taylor KM eds. Cardiac surgery and the brain. London: Edward Arnold, 1993: 34-54.
11. Pugsley WB. Assessment of microembolic load during cardiopulmonary bypass by transcranial Doppler techniques. In: Smith PL, Taylor KM eds. Cardiac surgery and the brain. London: Edward Arnold, 1993: 159-64.
12. Edmunds LH Jr, Colman RW, Niewiarowski S. Blood-surface interactions during cardiopulmonary bypass. In: Friedel N, Hefzer R, Royston D eds. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 27-36.
13. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552-59.
14. Schmidt B. Experimental test systems for the assessment of the blood compatibility of materials used in extracorporeal circuits. Nephrol Dial Transplant 1994; 9: 77-82.
15. Carmeda BioActive Surface. Compendium of Scientific Information, Summary of Experience. Medtronics Inc. 1991.
16. Larm O, Larsson R, Olsson P. Surface-immobilized heparin. In: Lane DA, Lindahl U eds. Heparin. Chemical and biological properties, clinical applications. Boco Raton, FL: CRC Press, 1989: 597-608.
17. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; ii: 1289-91.
18. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364-72.
19. Emerson TE Jr. Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovascular Drug Reviews 1989; 7: 127-40.
20. Pradhan MJ, Fleming JS, Nkere UU, Arnold J, Wildevuur CRH, Taylor KM. Clinical experience with heparin-coated cardiopulmonary bypass circuits. Perfusion 1991; 6: 235-42.
21. Giordano G, Formica M, Cavalli G et al. Activation of neutrophil oxidative metabolism during cardiopulmonary bypass with membrane oxygenators. ASAIO Trans 1989; 35: 368-69.
22. Gott VL, Whiffen JO, Datton RC. Heparin bonding on colloidal graphite surfaces. Science 1963; 142: 1297-98.
23. Wendel HP, Heller W, Gallimore MJ, Hoffmeister HE. Heparin-coated oxygenators significantly reduce contact system activation in an in-vitro cardiopulmonary bypass model. Blood Coagul Fibrinolysis 1994; 5: 673-78.
24. Toomasian JM, Hsu LC, Hirschl RB, Heiss KF, Hultquist KA, Bartlett RH. Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation. ASAIO Trans 1988; 34: 410-14.
25. Van der Kamp KWHJ, van Oeveren W. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery. I J Artif Organs 1993; 16: 836-42.
26. Dowling RD, Brown ME, Whittington RO, Quinlan JJ, Armitage JM. Clinical cardiopulmonary bypass without systemic anticoagulation. Ann Thorac Surg 1993; 56: 1176-78.
27. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocomparability of extracorporeal circulation: invitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991; 101: 654-60.
28. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 806-13.
29. Jansen PGM, Velthuis HT, Huybregts RAJM et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995; 110: 829-34.
30. Mollnes TE, Videm V, Riesenfeld J et al. Complement activation and bioincompatibility. Clin Exp Immunol 1991; 86: 21-26.
31. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Drug Res 1983; 33: 479-94.
32. Wachtfogel YT, Kucich U, Hack CE et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-10.
33. Laurel MTP, Ratnoff OD, Everson B. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol). J Lab Clin Med 1992; 119: 580-85.
34. Chan BMC, Brash JL. Adsorption of fibrinogen on glass: reversibility aspects. Journal of Colloid and Interface Science 1981; 82: 217-25.
35. Brash JL. Protein adsorption and blood interactions. In: Szycher M ed. Biocompatibile polymers, metals, and composites. Lancaster, PA: Technomic, 1983: 35-52.